Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AVADEL PHARMACEUTICALS PLC Director's Dealing 2025

Jul 31, 2025

31920_dirs_2025-07-31_a7cbe9d3-f23e-4a17-8dc5-67c29990f00a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AVADEL PHARMACEUTICALS PLC (AVDL)
CIK: 0001012477
Period of Report: 2025-07-29

Reporting Person: Glass Geoffrey Michael (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-07-29 Ordinary Shares A 11000 Acquired 22000 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-07-29 Stock Option (Right to Buy) $10.83 A 11000 Acquired 2035-07-29 Ordinary Shares (11000) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Ordinary Shares 69075 Indirect
Ordinary Shares 75904 Indirect

Footnotes

F1: Represents a restricted share award. The shares shall vest in full on the earlier to occur of (a) July 29, 2026 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time.

F2: These Ordinary Shares are held by The Geoffrey Glass Trust of which the Reporting Person is a co-trustee. The Reporting Person is the sole beneficiary of the trust.

F3: These Ordinary Shares are held by Geoffrey M. Glass Revocable Trust U/T/D August 26, 2020 of which the Reporting Person is trustee. The Reporting Person and members of his immediate family are the sole beneficiaries of the trust.

F4: The options shall vest in full on the earlier to occur of (a) July 29, 2026 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time.